Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Perspective Therapeutics (CATX) over the last 15 years, with Q3 2025 value amounting to $6.7 million.

  • Perspective Therapeutics' Accumulated Expenses rose 6878.77% to $6.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.7 million, marking a year-over-year increase of 6878.77%. This contributed to the annual value of $5.5 million for FY2024, which is 5267.56% up from last year.
  • As of Q3 2025, Perspective Therapeutics' Accumulated Expenses stood at $6.7 million, which was up 6878.77% from $5.0 million recorded in Q2 2025.
  • Perspective Therapeutics' Accumulated Expenses' 5-year high stood at $6.7 million during Q3 2025, with a 5-year trough of $240000.0 in Q1 2021.
  • Over the past 5 years, Perspective Therapeutics' median Accumulated Expenses value was $616000.0 (recorded in 2023), while the average stood at $1.9 million.
  • In the last 5 years, Perspective Therapeutics' Accumulated Expenses plummeted by 231.66% in 2022 and then soared by 115894.74% in 2023.
  • Quarter analysis of 5 years shows Perspective Therapeutics' Accumulated Expenses stood at $259000.0 in 2021, then increased by 10.04% to $285000.0 in 2022, then skyrocketed by 1158.95% to $3.6 million in 2023, then surged by 52.68% to $5.5 million in 2024, then rose by 22.51% to $6.7 million in 2025.
  • Its Accumulated Expenses was $6.7 million in Q3 2025, compared to $5.0 million in Q2 2025 and $2.9 million in Q1 2025.